Genfit S.A. ADR (GNFT)

Jan 13, 2025, 4:10 PM EST - 4 days ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Nov 13, 2024, 4:10 PM EST - 2 months ago

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Nov 7, 2024, 4:10 PM EST - 2 months ago

GENFIT Reports Third Quarter 2024 Financial Information

Sep 24, 2024, 8:51 AM EDT - 4 months ago

Top 4 Health Care Stocks That May Keep You Up At Night

BFRG DOCS GILD

Sep 23, 2024, 1:30 AM EDT - 4 months ago

GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Jul 26, 2024, 7:45 AM EDT - 6 months ago

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Jun 17, 2024, 4:10 PM EDT - 7 months ago

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

Jun 10, 2024, 5:22 PM EDT - 7 months ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

Jun 10, 2024, 5:08 PM EDT - 7 months ago

US FDA approves Genfit and Ipsen's liver disease drug

May 29, 2024, 4:10 PM EDT - 8 months ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

May 29, 2024, 1:52 PM EDT - 8 months ago

Genfit: Under The Radar Biotech With Upcoming Catalysts

May 22, 2024, 12:05 PM EDT - 8 months ago

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

May 14, 2024, 4:10 PM EDT - 8 months ago

GENFIT Reports First Quarter 2024 Financial Information

Apr 25, 2024, 4:10 PM EDT - 9 months ago

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Apr 15, 2024, 4:10 PM EDT - 9 months ago

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Apr 5, 2024, 2:00 PM EDT - 10 months ago

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Apr 4, 2024, 4:10 PM EDT - 10 months ago

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 4:10 PM EST - 11 months ago

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Jan 15, 2024, 4:10 PM EST - 1 year ago

GENFIT Announces 2024 Financial Calendar

Dec 8, 2023, 1:55 AM EST - 1 year ago

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Dec 6, 2023, 11:30 AM EST - 1 year ago

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

Nov 27, 2023, 7:30 AM EST - 1 year ago

Genfit: Large PBC Market, Liquidity To Await Approval

Nov 16, 2023, 4:10 PM EST - 1 year ago

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Nov 13, 2023, 4:30 PM EST - 1 year ago

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Nov 9, 2023, 4:10 PM EST - 1 year ago

GENFIT Reports Third Quarter 2023 Financial Information

Nov 2, 2023, 5:10 PM EDT - 1 year ago

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Sep 26, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

Sep 5, 2023, 4:10 PM EDT - 1 year ago

GENFIT to Participate in Upcoming Investor Conferences

Aug 10, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

Jun 30, 2023, 6:56 AM EDT - 1 year ago

These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.

AAPL NKE

Jun 30, 2023, 6:44 AM EDT - 1 year ago

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

Jun 30, 2023, 1:00 AM EDT - 1 year ago

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Jun 30, 2023, 1:00 AM EDT - 1 year ago

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Jun 7, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

May 31, 2023, 4:44 PM EDT - 1 year ago

Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

May 31, 2023, 4:10 PM EDT - 1 year ago

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

May 24, 2023, 1:00 PM EDT - 1 year ago

GENFIT: May 24, 2023 Combined Shareholders Meeting results

May 23, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

May 11, 2023, 4:10 PM EDT - 1 year ago

GENFIT Reports First Quarter 2023 Financial Information

May 11, 2023, 4:04 PM EDT - 1 year ago

Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling

May 9, 2023, 4:10 PM EDT - 1 year ago

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

Apr 27, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces Publication of Extra-Financial Performance Report 2022

Apr 19, 2023, 4:10 PM EDT - 1 year ago

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

Apr 18, 2023, 4:10 PM EDT - 1 year ago

GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F

Apr 13, 2023, 4:10 PM EDT - 1 year ago

GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 4:10 PM EST - 2 years ago

GENFIT Announces Revenues and Cash Position as of December 31, 2022

Feb 10, 2023, 8:47 AM EST - 2 years ago

Genfit: Catching Strong Bid With Emerging Data (Technical Analysis)

Jan 24, 2023, 4:10 PM EST - 2 years ago

GENFIT Announces 2023 Financial Calendar

Nov 17, 2022, 4:10 PM EST - 2 years ago

GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases

Nov 10, 2022, 4:10 PM EST - 2 years ago

GENFIT Reports Third Quarter 2022 Financial Information